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Purpose: Results from the Danish cluster-randomized trial of telehealthcare to 1,225 patients 
with chronic obstructive pulmonary disease (COPD), the Danish Telecare North Trial, concluded 
that the telehealthcare solution was unlikely to be cost-effective, by applying international 
willingness-to-pay threshold values. The purpose of this article was to assess potential sources of 
variation across subgroups, which could explain overall cost-effectiveness results or be utilized 
in future economic studies in telehealthcare research.
Methods: First, the cost-structures and cost-effectiveness across COPD severities were 
analyzed. Second, five additional subgroup analyses were conducted, focusing on differences 
in cost-effectiveness across a set of comorbidities, age-groups, genders, resource patterns 
(resource use in the social care sector prior to randomization), and delivery sites. All subgroups 
were  investigated post hoc. In analyzing cost-effectiveness, two separate linear mixed-effects 
models with treatment-by-covariate interactions were applied: one for quality-adjusted life-
year (QALY) gain and one for total healthcare and social sector costs. Probabilistic sensitivity 
analysis was used for each subgroup result in order to quantify the uncertainty around the 
cost-effectiveness results.
Results: The study concludes that, across the COPD severities, patients with severe COPD 
(GOLD 3 classification) are likely to be the most cost-effective group. This is primarily due 
to lower hospital-admission and primary-care costs. Telehealthcare for patients younger than 
60 years is also more likely to be cost-effective than for older COPD patients. Overall, results 
indicate that existing resource patterns of patients and variations in delivery-site practices 
might have a strong influence on cost-effectiveness, possibly stronger than the included health 
or sociodemographic sources of heterogeneity.
Conclusion: Future research should focus more on sources of heterogeneity found in the 
implementation context and the way telehealthcare is adopted (eg, by integrating formative 
evaluation into cost-effectiveness analyses).
Trial registration: Clinicaltrials.gov, NCT01984840.
Keywords: COPD, telemonitoring, telehealth, health economics, heterogeneity, Denmark
Introduction
Trial-based evidence on the cost-effectiveness of telehealthcare for patients with chronic 
obstructive pulmonary disease (COPD) is accumulating.1–8 This evidence addresses 
whether or not the relative treatment effect of an intervention (ie, telehealthcare) 
compared to some alternative (ie, typically usual care) is worth any additional costs.9 
Most of these studies have too few patients to make subgroup analysis meaningful, 
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and the large-scale Whole System Demonstrator study 
has only reported main cost-effectiveness results from all 
included patients with diabetes, chronic heart failure, and 
COPD. Because patients are heterogeneous and have complex 
healthcare needs, cost-effectiveness is likely to vary with 
different baseline factors, such as health status, sociodemo-
graphic characteristics, or other baseline characteristics.10 
Although some studies have reported a direct relationship 
between COPD severity and costs,11,12 there is very little 
knowledge of the relative cost-structures and heterogeneity 
of cost-effectiveness for patients with COPD that are specific 
for telehealthcare research.13
The recently reported Danish cluster-randomized trial of 
telehealthcare (Danish Telecare North Trial) among 1,225 
patients with COPD reported additional costs, similar gain 
in quality-adjusted life-years (QALYs), and a relatively high 
incremental cost-effectiveness ratio (ICER) compared to 
international willingness-to-pay threshold (WTP) values, 
making the telehealthcare solution unlikely to be cost-
effective.14 However, subgroups of patients with COPD 
within the trial could be more or less cost-effective, and 
these tendencies are important in order to explain the overall 
cost-effectiveness outcome, as input to decision-models such 
as the recently conducted study by Hofer et al15 or simply to 
create informed hypotheses for use in the design of future 
trial-based economic evaluations.
The objective of this article is to present cost-effectiveness 
results across a range of plausible subgroups in the cluster-
randomized Danish Telecare North Trial. The subgroups 
are COPD severity in particular (classified according to 
the Global Initiative for Chronic Obstructive Lung Disease 
[GOLD]), but also three different comorbidities (coronary 
heart disease, diabetes, or mental health problems), gender, 
age, and existing resource patterns as well as delivery site.
Methods
The study protocol16 and the overall results from the economic 
evaluation14 have been published elsewhere, but a brief sum-
mary is provided in Table 1.
Patients in the intervention group received a set of tele-
healthcare equipment and were monitored by a municipality- 
based healthcare team consisting primarily of nurses. 
Furthermore, patients received disease-specific education. 
The control group received usual care. In total, 1,225 patients 
satisfied the exclusion and inclusion criteria; 26 municipal-
ity districts across 10 different municipalities/delivery sites 
defined the randomization units (13 in each arm). These 
districts were matched, so that all municipalities/delivery sites 
contained municipality districts with patients who received 
telehealthcare or usual care16; 578 patients were randomized 
to telehealthcare, and 647 to usual care.
The primary outcome for the cost-effectiveness analy-
sis was total healthcare and social sector costs per QALY 
gained. Costs included intervention costs, healthcare costs 
(patient-level hospital-, medicine-, and primary sector 
costs), and social sector costs (patient-level costs associ-
ated with practical help and care at home, home-based 
nursing care, and rehabilitation). The duration of the study 
was 12 months.16
No subgroup analyses were pre-defined in the trial pro-
tocol, but different baseline characteristics were collected as 
part of the trial. These included forced expiratory volume 
Table 1 Overview of economic evaluation of the Danish Telecare north Trial
Perspective of analysis Healthcare sector and social care sector
Outcomes Total costs per QalY gained
Compared alternatives ig: a set of telehealthcare equipment and were monitored by a community-based healthcare team (based in social care 
sector). Patients also received disease-specific education 
Cg: usual care
Duration of study 12 months
Patients included All patients with COPD that may benefit from telehealthcare. Fixed residence in North Denmark Region, Danish speaking, 
gsM coverage or phone line. no cognitive impairments. n=1,225 patients; 578 in ig and 647 in Cg
Clusters Municipality districts (social care sector), 26 clusters in total, 13 in each treatment arm. Each municipality had at least one 
district in both the intervention and control groups
Cost categories hospital admissions, outpatient visits including emergency contacts, primary-care contacts, prescribed medicine, personal 
care, practical help, at-home nursing care, and rehabilitation
Conclusion incremental QalYs was 0.0132 (rounded) 
incremental total costs were €728 (rounded) 
iCER was €55.327 per QalY gained 
Telehealthcare is unlikely to be cost-effective
Abbreviations: QalY, quality-adjusted life-year; ig, intervention group; Cg, control group; COPD, chronic obstructive pulmonary disease; gsM, global system for mobiles; 
iCER, incremental cost-effectiveness ratio.
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in 1 second (FEV1%) measured by the patients’ general 
practitioner. Presence of comorbidities was ascertained 
from questionnaires that were filled out by the patients’ 
general practitioner. Age and gender were identified from 
the patients’ social security number. Patient-level resource 
use from both within the trial period and 1 year prior to 
randomization was collected from medical registers by 
applying patients’ social security number. National-level 
patient data for all hospital contacts were collected from 
the Danish National Patient Register;17 all contacts between 
patients and the primary care sector from the National 
Health Insurance Service Register;18 and medication use 
was taken from The Danish Register of Medicinal Product 
Statistics.19 Patient-level community care service was taken 
from care systems in each of the 26 included municipality 
districts. Intervention costs included costs of hardware and 
peripherals, installation and deinstallation costs, main-
tenance and support costs, training costs for health care 
professionals, patient-specific training, monitoring costs, 
and project management costs. QALYs were calculated 
by linear interpolation of EQ5D-3L scores with Danish 
societal weights.20 More details on the data are described 
in the overall within-trial economic evaluation.14 
The study was conducted in accordance with the Declara-
tion of Helsinki. The trial has been presented to the Regional 
Ethical Committee for Medical Research in the North 
Denmark Region, where it was determined that no ethical 
approval was necessary. The trial has also been authorized 
by the Danish Data Protection Agency. All patients signed 
an informed consent form before taking part in the clinical 
trial. Trial registration: Clinicaltrials.gov, NCT01984840.
statistical analysis
The statistical analysis employed in this article followed 
the analytical strategy from a cost-effectiveness article 
published previously.14 An intention-to-treat principle was 
applied. Missing data were assumed missing at random 
(MAR) and were imputed according to methodological 
guidelines.21
To allow for inclusion of particularly COPD severity-spe-
cific costs in future decision-modeling studies, the unadjusted 
cost structure across treatment alternatives was analyzed. 
These cost-structures are presented for each of the applied 
cost-categories mentioned earlier. Results are presented as 
means [standard deviation (SD)] and between-group differ-
ences are reported as raw mean difference and standardized 
difference (SMD = difference between randomization group 
averages/SD of the total sample) to allow for meta-analyses.
Estimation of incremental total costs and incremental 
QALYs in all subgroups was based on two separate linear 
mixed-effects models with treatment-by-covariate interac-
tions. Total costs were controlled for relevant subgroup 
interaction on the treatment variable, baseline EQ5D score, 
baseline costs, age, baseline FEV1%, presence of musculo-
skeletal disease, and clustering. Similarly, QALYs gained 
were controlled for the relevant subgroup interaction term 
on the treatment identifier, baseline EQ5D score, age, gen-
der, baseline FEV1%, marital status, presence of diabetes, 
presence of cancer, and clustering. By applying the “mi 
estimate: xtmixed” command with robust standard errors in 
STATA12.1, a deterministic ICER estimate was calculated 
for each subgroup by linear combination of the relevant 
treatment beta-coefficients in both models. More details on 
the applied linear mixed-effects models are available in the 
Supplementary material. To quantify the uncertainty around 
these estimates, a series of probabilistic sensitivity analyses 
were conducted. The output from both models was exported 
to Microsoft Excel 2010 along with Cholesky’s decomposi-
tion matrix, and 5,000 new parameter estimates from the 
analytical models from normal distributions were drawn. 
Estimates of incremental QALYs and incremental total costs 
were created to present the probability that telehealthcare was 
cost-effective as a function of decision-makers; WTP for extra 
QALYs. The probabilities that telehealthcare is cost-effective 
are presented at €25,000 and €40,000, which is roughly the 
threshold values applied in the UK (1€=0.73 £).
Results
Complete data for both total costs (ie, all cost-categories) 
and EQ5D scores at baseline and follow-up were available 
for 751 patients (61%; 325 in the telehealthcare group; 426 
in the control group). Incomplete data stemmed primarily 
from non-response or from incomplete registration of EQ5D 
questionnaire items (8% had missing EQ5D summary scores 
at baseline; 27% at follow-up); 12% had missing values on 
one cost-category – rehabilitation; 103 patients died during 
the trial period (8%).
The telehealthcare and usual care group were similar at 
baseline (Table 2). The general tendency is that patients in 
the intervention group have slightly worse health (higher 
proportion of patients with severe COPD [GOLD 3], more 
comorbidities, and greater resource use in municipalities 
prior to randomization). There were also more men in the 
 telehealthcare group. Between-group difference across 
 delivery sites was expected given the randomization 
procedure.
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Subgroups defined by COPD severity
The unadjusted cost-structure across GOLD classifications is 
presented in Table 3. For patients with mild COPD (GOLD  1), 
telehealthcare was associated with higher total costs (raw 
mean difference €2401) giving rise to an SMD of 23.37%. 
This was primarily driven by higher social sector costs – that 
is, help and care at home (raw mean difference €513; SMD 
12.82%), home nursing care (raw mean difference €1380; 
SMD 26.21%), and rehabilitation (raw mean difference €89; 
SMD 35.85%). Patients in the telehealthcare group had fewer 
costs due to primary-care visits (raw mean difference −€123, 
standardized between-group difference; −25.01%).
Telehealthcare was associated with higher total costs 
for patients with moderate COPD (GOLD 2; raw mean 
 difference €1424; SMD 16.94%). The telehealthcare group 
had higher costs due to hospital admissions (raw mean dif-
ference €489; SMD 11.72%) and home nursing care (raw 
mean difference €236; SMD 9.40%). There were fewer 
costs due to help and care at home (raw mean difference 
−€186; SMD −4.81%).
Total costs for patients with very severe COPD (GOLD 4) 
was associated with higher total costs in the telehealthcare 
group (raw mean difference €6400; SMD 31.87%). Higher 
costs were accrued across all cost categories.
In contrast to other COPD severities, patients with severe 
COPD (GOLD 3) had fewer total costs in the telehealthcare 
group (raw mean difference −€717; SMD −4.49%). This 
was driven by cost savings in hospital admissions (raw mean 
Table 2 Baseline characteristics
Subgroup category Telehealthcare Usual care Difference Fisher’s exact test
n=578 n=647 Raw P-value
COPD severity (GOLD classification 1–4)     
Mild, gOlD 1 3.98 (n=23) 4.64 (n=30) −0.66
0.937
Moderate, gOlD 2 31.49 (n=182) 31.07 (n=201) 0.42
severe, gOlD 3 32.18 (n=186) 30.60 (n=198) 1.58
Very severe, gOlD 4 13.84 (n=80) 13.91 (n=90) −0.07
Missing 18.51 (n=107) 19.78 (n=128) −1.27
Comorbidities    
Coronary heart disease 32.70 (n=189) 31.84 (n=206) 0.86 0.927
Diabetes 10.21 (n=59) 9.89 (n=64) 0.32 0.962
Mental health problem 4.84 (n=28) 4.79 (n=31) 0.05 0.991
Missing 8.13 (n=47) 7.88 (n=51) 0.25
Age§    
<60 years 16.78 (n=97) 14.68 (n=95) 2.10
0.445
60–69 years 34.08 (n=197) 31.68 (n=205) 2.40
70–79 years 36.33 (n=210) 40.19 (n=260) −3.86
≥80 years 12.80 (n=74) 13.45 (n=87) −0.65
Men§ 48.27 (n=279) 43.74 (n=283) 4.53 0.063
Existing resource pattern    
no resource use in social sector 12 months prior to 
randomization
52.25 (n=302) 57.50 (n=372) −5.25
0.136Resource use in social sector 12 months prior to 
randomization
39.62 (n=229) 36.32 (n=235) 3.30
Missing 8.13 (n=47) 6.18 (n=40) 1.95
Delivery site
Delivery site 1 8.13 (n=47) 6.18 (n=40) 1.95
0.000
Delivery site 2 16.09 (n=93) 4.33 (n=28) 11.76
Delivery site 3 10.73 (n=62) 9.58 (n=62) 1.15
Delivery site 4 5.54 (n=32) 5.10 (n=33) 0.44
Delivery site 5 6.40 (n=37) 7.88 (n=51) −1.48
Delivery site 6 3.46 (n=20) 4.17 (n=27) −0.71
Delivery site 7 4.50 (n=26) 4.33 (n=28) 0.17
Delivery site 8 15.40 (n=89) 6.49 (n=42) 8.91
Delivery site 9 10.55 (n=61) 10.05 n=65) 0.50
Delivery site 10 19.30 (n=111) 41.89 (n=271) −22.59
Note: Data are presented as percentages (number of patients). §Variable has no missing values.
Abbreviations: COPD, chronic obstructive pulmonary disease; gOlD, global initiative for Chronic Obstructive lung Disease.
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 difference −€1429; SMD −10.73%) and primary sector con-
tacts (raw mean difference −€76; SMD −14.46%).
From Table 4, the ICER point estimates indicate that the 
telehealthcare intervention was dominant for patients with 
severe COPD (GOLD 3), with a probability of achieving 
cost-effectiveness of 68% at a WTP threshold of €25,000 
and 70% at €40,000. The probability that telehealthcare is 
cost-effective remains consistently lower across different 
Table 3 average costs (€) per patient across treatment groups at 12-month follow-up for all COPD severities
Cost categories across COPD severities Telehealthcare Usual care Between-group difference
Mean (SD) Mean (SD) Raw mean Standardized (%)*
Mild COPD (GOLD 1)
hospital contacts
admissions 768 (4879) 813 (2449) −45.16 −1.22
Outpatient/emergency department visits 111 (291) 97 (274) 14.58 5.17
Primary-care contacts 602 (420) 725.7 (535) −123.32 −25.01
Municipality-care contacts
help and care at home 1174 (5128) 661 (2868) 512.96 12.82
home nursing care 1857 (7782) 477 (1524) 1379.50 26.21
Rehabilitation§ 106 (325) 17 (157) 88.90 35.85
Medicine 1025 (714) 1085.3 (726) −60.85 −8.43
Total service costs (excluding intervention costs) 5645 (14486) 3878 (6079) 1766.58 17.22
Total costs (including intervention costs) 6280 (14464) 3878 (6079) 2401.58 23.37
Moderate COPD (GOLD 2)
hospital contacts
admissions 1299 (5369) 811 (2653) 488.67 11.72
Outpatient/emergency department visits 194 (450) 123 (348) 71.80 17.90
Primary-care contacts 618 (397) 616 (475) 1.93 0.44
Municipality-care contacts
help and care at home 946 (3495) 1132 (4168) −186.12 −4.81
home nursing care 625 (2893) 388 (2111) 236.36 9.40
Rehabilitation§ 50 (265) 24 (191) 25.56 11.14
Medicine 1312 (856) 1240 (795) 71.79 8.70
Total service costs (excluding intervention costs) 5045 (8992) 4334 (7796) 709.98 8.46
Total costs (including intervention costs) 5759 (8988) 4334 (7796) 1424.25 16.94
Severe COPD (GOLD 3)
hospital contacts
admissions 2686 (8818) 4116 (16371) −1429.47 −10.73
Outpatient/emergency department visits 347 (564) 346 (583) 0.92 0.16
Primary-care contacts 602 (460) 679 (582) −76.39 −14.46
Municipality-care contacts
help and care at home 1990 (5654) 1968 (5934) 22.58 0.39
home nursing care 680 (1805) 638 (2559) 42.72 1.92
Rehabilitation§ 116 (462) 106 (533) 10.64 2.13
Medicine 1722 (855) 1721 (1035) 0.54 0.06
Total service costs (excluding intervention costs) 8144 (11826) 9572 (19000) −1428.47 −8.94
Total costs (including intervention costs) 8855 (11807) 9572 (19000) −716.92 −4.49
Very severe COPD (GOLD 4)
hospital contacts
admissions 6670 (21124) 4619 (12368) 2051.10 12.02
Outpatient/emergency department visits 728 (801) 527 (737) 200.35 25.88
Primary care contacts 571 (422) 518 (408) 53.01 12.76
Municipality care contacts
help and care at home 4202 (9588) 1340 (3435) 2862.11 39.93
home nursing care 775 (2475) 616 (1934) 158.84 7.20
Rehabilitation§ 133 (422) 57 (246) 75.43 22.04
Medicine 2176 (1659) 1863 (946) 312.54 23.36
Total service costs (excluding intervention costs) 15255 (24517) 9541 (14497) 5713.38 28.52
Total costs (including intervention costs) 15941 (24506) 9541 (14497) 6399.81 31.87
Note: *standardized difference, difference between randomization group averages divided by the standard deviation (sD) of the total sample. §imputed data.
Abbreviations: COPD, chronic obstructive pulmonary disease; gOlD, global initiative for Chronic Obstructive lung Disease.
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levels of WTP threshold values for other COPD severities 
(Figure 1). Usual care was dominant for moderate COPD 
(GOLD 2), with a probability of achieving cost-effectiveness 
of 35% at a WTP threshold of €25,000 and 35% at €40,000.
Subgroups defined by comorbidities, 
gender, age, resource patterns, and 
delivery site
In Table 5, the ICER point estimate is dominant for telehealth-
care for patients younger than 60 years, with a probability of 
achieving cost-effectiveness of 69% at a WTP threshold of 
€25,000 and 68% at €40,000. A relatively high probability 
of achieving cost-effectiveness is present for patients aged 
80 and older (62% at a WTP threshold of €25,000 and 71% 
at €40,000). Telehealthcare is dominant and has a high prob-
ability of achieving cost-effectiveness, given the data for the 
subgroup with patients having resource use (practical help, 
home nursing care, and rehabilitation) in the municipalities 
at some point 12 months prior to randomization (89% at a 
WTP threshold of €25,000 and 89% at €40,000). Across 
municipalities/delivery sites, there are large variations in 
cost-effectiveness with probabilities of cost-effectiveness 
Table 4 Cost-effectiveness of telehealthcare compared to usual care across COPD severities
COPD severity 
(GOLD classification 
1–4)#
QALY Wald 
test*
Total costs (€) Wald 
test*
ICER Pr(cost- 
effective)
Pr(cost- 
effective)
Between group  
difference (95% CI)
P-value Between group 
difference  
(95% CI)
P-value (€ per  
QALY)
at €25,000 at 
€40,000
Mild, gOlD 1 (6%) 0.0281 (–0.0551; 0.1113) 0.4131 1872 (–5337; 9082) 0.3998 66,577 39% 44%
Moderate, gOlD 2 (38%) –0.0113 (–0.0469; 0.0243) 1455 (–94; 3003) UC dominant 35% 35%
severe, gOlD 3 (39%) 0.0302 (–0.0075; 0.0678) –964 (–3750; 1822) ThC dominant 68% 70%
Very severe, gOlD 4 (17%) 0.0229 (–0.0261; 0.0719) 2959 (–2087; 8005) 129,035 29% 33%
Note: *Wald test for interaction between treatment and the subgroup variables. #QalYs and total costs were not simultaneously controlled for baseline FEV1%. all results 
are imputed.
Abbreviations: QalY, quality-adjusted life-years; COPD, chronic obstructive pulmonary disease; UC, usual care; ThC, telehealthcare; gOlD, global initiative for Chronic 
Obstructive lung Disease; iCER, incremental cost-effectiveness ratio; Pr, probability.
Figure 1 Probability of telehealthcare being cost-effective, depending on the severity of COPD (by GOLD classification).
Abbreviations: COPD, chronic obstructive pulmonary disease; QalY, quality-adjusted life-years; gOlD, global initiative for Chronic Obstructive lung Disease.
10,000 20,000 30,000 40,000 50,000
Threshold €/QALY
60,000 70,000 80,000 90,000 100,000
Mild COPD (GOLD 1)
Moderate COPD (GOLD 2)
Severe COPD (GOLD 3)
Very severe COPD (GOLD 4)
1
0.9
0.8
0.7
0.6
0.5
Pr
ob
ab
ilit
y
0.4
0.3
0.2
0.1
0
0
 
C
lin
ic
oE
co
no
m
ic
s 
an
d 
O
ut
co
m
es
 R
es
ea
rc
h 
do
w
nl
oa
de
d 
fr
om
 h
ttp
s:
//w
w
w
.d
ov
ep
re
ss
.c
om
/ b
y 
13
0.
22
5.
19
8.
22
4 
on
 1
2-
O
ct
-2
01
7
F
or
 p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
ClinicoEconomics and Outcomes Research 2017:9 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
397
Danish Telecare north Trial: cost-effectiveness analysis of subgroups
ranging from low probabilities of cost-effectiveness (eg, 0%) 
to very high (eg, 100%) at the applied WTP threshold values. 
This is primarily due to cost savings.
Furthermore, from Table 5, it can be seen that no dominant 
courses of action can be found for comorbidities or gender. 
There is a tendency for coronary heart disease and diabetes 
to reduce the likelihood of achieving cost-effectiveness of 
telehealthcare (ICER point estimates increases from €26,527 
Table 5 Cost-effectiveness of telehealthcare compared to usual care in subgroups
Subgroup category QALY Wald 
test*
Total costs (€) Wald 
test*
ICER Pr(cost-
effective)
Pr(cost-
effective)
Between group  
difference (95% CI)
P-value Between group 
difference (95% CI)
P-value (€ per 
QALY)
at 
€25,000
at €40,000
Comorbidities        
Coronary heart disease
no (65%) 0.0168 (–0.0059; 0.0394) 0.636 445 (–1604; 2493) 0.566 26,527 49% 57%
Yes (35%) 0.0068 (–0.0315; 0.0451) 1290 (–650; 3229) 189,373 28% 31%
Diabetes
no (89%) 0.0112 (–0.0116; 0.3402) 0.577 309 (–1340; 1957) 0.182 27,573 49% 56%
Yes (11%) 0.0294 (–0.0312; 0.090) 4731 (–1085; 10547) 160,728 8% 12%
Mental health problem
no (95%) 0.0130 (–0.0094; 0.0354) 0.911 772 (–770; 2314) 0.815 59,378 29% 39%
Yes (5%) 0.0178 (–0.0627; 0.0983) 38 (–5837; 5913) 2,135 55% 58%
Gender      
Female (54%) 0.0052 (–0.0172; 0.0276) 0.347 407 (–1471; 2286) 0.573 77,890 39% 42%
Male (46%) 0.0225 (–0.0108; 0.0557) 1122 (–888; 3132) 49,917 44% 55%
Age##      
<60 years (16%) 0.0046 (–0.0403; 0.0495) 0.692 –560 (–2972; 1851) 0.707 ThC dominant 69% 68%
60–69 years (33%) 0.0009 (–0.0322; 0.0340) 1622 (–1170; 4415) 1,764,487 22% 25%
70–79 years (38%) 0.01607 (–0.0211; 0.0532) 528 (–1848; 2903) 32,845 47% 51%
≥80 years (13%) 0.0489 (–0.0202; 0.1180) 484 (–2117; 3085) 9,900 62% 71%
Patients with 
previous resource 
use in social sector
     
no resource use 
in social sector 
12 months prior to 
randomization (64%)
0.0180 (–0.0054; 0.0414) 0.894 1396 (290; 2503) 0.228 77,622 7% 18%
Resource use 
in social sector 
12 months prior to 
randomization (36%)
0.0143 (–0.0322; 0.0607) –1205 (–5144; 2734) ThC dominant 89% 89%
Delivery site
Delivery site 1 (7%) 0.0675 (0.0357; 0.0993) 0.102 3952 (2952; 4952) 0.000 58,520 0% 6%
Delivery site 2 (10%) –0.0033 (–0.0311; 0.0245) 3375 (1870; 4881) UC dominant 1% 3%
Delivery site 3 (10%) 0.0033 (–0.0712; 0.0779) –12 (–2344; 2319) ThC dominant 55% 56%
Delivery site 4 (5%) 0.0397 (0.0061; 0.0732) –290 (–1026; 446) ThC dominant 90% 93%
Delivery site 5 (7%) –0.0007 (–0.0322; 0.0308) –981 (–2985; 1023) 1,389,780 71% 70%
Delivery site 6 (4%) 0.0308 (–0.0117; 0.0733) –9138 (–12087; –6188) ThC dominant 100% 100%
Delivery site 7 (4%) 0.0193 (–0.0171; 0.0557) 262 (–248; 772) 13,549 58% 64%
Delivery site 8 (11%) 0.0383 (–0.0027; 0.0792) –2545 (–2848; –2242) ThC dominant 100% 100%
Delivery site 9 (10%) 0.0160 (–0.0032; 0.0353) 416 (72; 759) 25,921 51% 59%
Delivery site 10 (32%) 0.0028 (–0.0379; 0.0435) 1062 (94; 2029) 376,794 19% 26%
Note: *Wald test for interaction between treatment and the subgroup variable. ##QalYs and total costs were not simultaneously controlled for age. all results are imputed.
Abbreviations: QalY, quality adjusted life year; COPD, chronic obstructive pulmonary disease; UC, usual care; ThC, telehealthcare; gOlD, global initiative for Chronic 
Obstructive lung Disease; iCER, incremental cost-effectiveness ratio; Pr, probability.
per QALY with no comorbidities to €189,373 per QALY 
with coronary heart disease, and from €27,573 per QALY 
to €160,724 per QALY with diabetes). Telehealthcare for 
patients with mental illness, on the other hand, seems more 
likely to be cost-effective, since the ICER point estimate 
changes from €59,378 per QALY without mental illness to 
€2,135 per QALY with mental health problems. The results 
also contain tendencies for telehealthcare to men to be more 
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cost-effective than for women (ICER €49,917 per QALY 
for men and €77,890 per QALY for women), because they 
achieve a higher QALY gain, albeit also higher costs. But 
uncertainties, particularly surrounding gender, are large.
Discussion
Based on the trial-based economic evaluation in the cluster-
randomized Danish Telecare North Trial,14 this subgroup 
analysis demonstrates no statistically significant differences 
in incremental QALYs and incremental total costs, except for 
costs across municipalities/delivery sites. The tendency is that 
incremental QALYs are small and positive across subgroups 
(except for patients with moderate COPD [GOLD 2] and for 
patients in some delivery sites). Therefore, cost-effectiveness 
results in subgroups mostly reflect that cost savings have 
occurred here.
Telehealthcare for patients with severe COPD (GOLD 3) 
is more likely to be cost-effective than in other COPD severi-
ties. This was primarily driven by cost savings in hospital 
admissions and primary-care contacts. Telehealthcare for 
patients with other COPD severities is less likely to be 
cost-effective due to higher total costs. Results also indicate 
that existing resource patterns of patients and delivery site 
might have a strong influence on cost-effectiveness, possibly 
stronger than the included health or sociodemographic char-
acteristics. Furthermore, telehealthcare for patients younger 
than 60 years is more likely to be cost-effective. No firm 
cost-effectiveness conclusions could be made of the included 
comorbidities and gender.
strengths and limitations
To date, there is almost no knowledge of heterogeneity in cost-
effectiveness for COPD patients in telehealthcare research. 
This study has sought to nuance the available evidence by 
presenting incremental costs, incremental QALYs, and the 
uncertainty around these estimates in a set of subgroups 
from an economic evaluation alongside a relatively large 
clinical trial. These subgroup analyses follow analytical good 
practices when presenting heterogeneity analyses in cost-
effectiveness research by presenting treatment-by-covariate 
interaction from a single clinical trial22 that makes use of 
patient-level data routinely captured in Danish registers. We 
have also quantified the uncertainty surrounding the cost 
and QALY estimates by probabilistic sensitivity analysis.22
On the other hand, if the study should be used for inferen-
tial purposes, it is a limitation that analyses were conducted 
post hoc and that there is no statistical power to conclude that 
the differences found are no more than random noise in the 
data. However, this is a weakness that is shared with most 
cost-effectiveness studies conducted alongside clinical trials, 
which are usually only powered to test differences in some 
clinical measure. Another limitation of the study is that only 
61% of the participants had complete registrations of all cost 
categories and EQ5D summary scores.
Comparison with other studies
Early studies on cost-effectiveness of patients with COPD 
have focused on patients with severe or very severe COPD 
(GOLD 3 and GOLD 4).1–6 They all demonstrate a potential 
for cost savings without sacrificing effect, although the 
methodological quality is rather low.23 This study included 
patients with all GOLD 1–4 severities and pinpoints that 
telehealthcare for GOLD 3 classified patients is more likely 
to be cost-effective and even potentially cost saving. Further-
more, a recently published economic evaluation for GOLD 
3 patients concluded that telehealthcare was not likely to be 
cost-effective, except maybe for patients without comor-
bidities.24 Although the uncertainty around this conclusion is 
high, the fact that the absence of comorbidities is important 
for achieving cost-effectiveness – depending on the type of 
comorbidity – is also indicated in this study. Another recently 
published economic evaluation concluded that telehealthcare 
was unlikely to be cost-effective for the patients with COPD 
who were included.8 The study included 256 patients with all 
COPD severities, but only 34% patients with severe COPD. 
Moreover, 68% of subjects had one or more comorbidities. 
Applying the conclusions from this subgroup analysis might 
explain this result.
implications for clinicians and decision-
makers
A major challenge in assessing telehealth is that its adoption 
may give rise to various organizational impacts.25 Cost-
effectiveness may depend on how it is embodied in existing 
healthcare delivery practices (eg, differences in healthcare 
practices or motivation and experiences of caregivers and 
patients). This study indicates that patient’s existing resource 
pattern is important for achieving cost-effectiveness. A 
plausible reason could be that, if healthcare profession-
als responsible for monitoring the patients are unfamiliar 
with a particular patient’s history or exacerbation behavior, 
telehealthcare might be at risk of being an add-on to usual 
care and not a substitute, because it is difficult for them to 
evaluate whether a patient is in need of hospital admission 
during an exacerbation or if the exacerbation could be han-
dled in another more cost-effective way. Furthermore, when 
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telehealthcare is implemented, patients could become more 
aware of their disease, or delivery sites could discover patients 
with COPD that had an unmet need for treatment and care 
that would not have been discovered otherwise. In our study, 
this could explain the probabilities of cost-effectiveness for 
patients with or without resource use in municipalities prior 
to randomization. This would mean that the implementa-
tion context of telehealthcare is important for achieving 
cost-effectiveness. Variations in practices, workflow, and 
management attention across healthcare delivery sites are 
also plausible,26,27 but not quantified in this study.
Future studies
Despite more than two decades of research, it is still not 
possible unequivocally to identify which types of telehealth-
care technologies would be cost-effective for certain patient 
types.28 One possible reaction is to suggest that it is “time 
to pause” the widespread application of telehealthcare until 
well-designed longer term multicenter studies with appropri-
ate follow-up (ie, continue summative evaluation but possibly 
with more ambitious or complicated analytical designs) have 
proven the benefits of the technology.29 Another reaction is to 
focus more on the context of implementation by seeking to 
integrate formative evaluation designs in cost-effectiveness 
analyses. Future research should focus more on contextual 
and/or implementation factors for telehealthcare adoption – 
for example, behavior and engagement of patients and health 
professionals; how organizational cultures, incentive systems, 
and management support the adoption of telehealthcare; or 
how telehealthcare could be embedded in existing workflows. 
This work should be focused on explaining how context and 
implementation factors are related to differences in included 
cost-categories or perceptions of health-related quality of life 
in order to achieve cost-effectiveness.
Some contexts and implementation factors may be dif-
ficult to identify or define a priori. In fact, one could argue 
that valuable information would be lost if post hoc subgroup 
analyses are not conducted due to clinical research practices 
and the fear of data-dredging. That a heterogeneity analysis 
has been conducted post hoc must, therefore, not routinely 
be an obstacle for learning more about the consequences of 
implementing medical technologies such as telehealthcare.
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Supplementary material
Details of the applied linear mixed-effects 
models
This study applied linear mixed-effects models, which are also 
known in the literature as random effects models, multilevel 
models, or hierarchical linear models. Linear mixed-effects 
models are used to analyze data that have a hierarchical or 
nested structure1 (eg, patients nested in hospitals, repeated 
measurements taken from the same in individuals, or, as in 
this case, patients within municipality districts).
Linear mixed-effects models can be used in cost-effec-
tiveness research conducted alongside cluster-randomized 
trials (ie, where randomization is conducted at a different 
level than the individual patients – in this case, municipality 
districts),2–4 because it is plausible that resource consumption 
or costs, health-related quality of life, or death to a certain 
degree, might be more similar within clusters than they are 
across clusters. This cluster effect must be taken into account 
in order to obtain valid parameter estimates and standard 
errors due to the violation of the independence assumption 
between observations in ordinary least squares regression.1–3
Mixed models contain both fixed effects and random 
effects. Fixed effects are analogous to standard OLS regres-
sion coefficients and are estimated directly. However, ran-
dom effects are not directly estimated but are summarized 
according to the variance–covariance structure of the model.1
A basic two-level linear mixed-effects model with two 
covariates for both total costs and QALY gain with treatment-
by-covariate interaction is presented below:
Total cost
ij  
=  γ
0
 + γ
1
T
j
*Z
ij
 + X
ij
 + r
j
 + e
ij
QALY
ij
  =  β
0
 + β
1
T
j
*Z
ij 
+ X
ij
 + s
j
 + u
ij
Where i is the patient identification number; j the cluster 
identification number; β
0
 and γ
0 
are model intercepts, and 
T
j
 the treatment indicator (T
j 
= 0 for clusters in control 
group; T
j 
= 1 for clusters in intervention group). γ
1 
and β
1 
are incremental total costs and incremental QALYs; Z
ij 
is
 
the 
covariate variable used in the particular subgroup analysis; 
X
ij
 is an additional covariate, r
j
 and s
j 
are random components, 
which represent the differences in the cluster mean costs and 
outcomes from the overall means in each treatment group, 
and, finally, ε
ij 
and u
ij 
are error terms to the model that are 
assumed normally distributed.
In our study, this basic tow-level model was expanded 
with the mentioned additional covariates to allow for baseline 
adjustment of the treatment effects found in each subgroup 
analysis (total costs models were controlled for baseline 
EQ5D-score, baseline costs, age, baseline FEV1%, presence 
of musculoskeletal disease, and clustering; QALY models 
were controlled for baseline EQ5D score, age, gender, base-
line FEV1%, marital status, presence of diabetes, presence 
of cancer, and clustering).
In STATA 12.1 the xtmixed procedure can be used to fit 
linear mixed models by maximum likelihood estimation.5
A reference category in each subgroup was used, and 
treatment effects for other subgroup categories were found 
by linear combination of treatment effects within subgroups. 
A deterministic incremental cost-effectiveness ratio (ICER) 
is then found by dividing each treatment effect found in the 
totalcost regression (γ
1
) with each treatment effect found in 
the QALY regression (β
1
).
References
1. Rabe-Hesketh S, Skrondal A. Multilevel and Longitudinal Modeling 
Using Stata. Volume I: Continuous Responses. 3rd ed. Texas: Stata Press; 
2012.
2. Gomes M, Grieve R, Nixon R, Ng ES, Carpenter J, Thompson SG. 
Methods for covariate adjustment in cost-effectiveness analysis that use 
cluster randomised trials. Health Econ. 2012;21(9):1101–1118.
3. Gomes M, Ng ES, Grieve R, Nixon R, Carpenter J, Thompson SG. 
Developing appropriate methods for cost-effectiveness analysis of cluster 
randomized trials. Med Decis Making. 2012;32(2):350–361.
4. Bachmann MO, Fairall L, Clark A, Mugford M. Methods for analyzing 
cost effectiveness data from cluster randomized trials. Cost Eff Resour 
Alloc. 2007;5(Icc):12.
5. Stata Press. xtmixed: Multilevel mixed-effects linear regression. Stata 
12 User’s Guide. 2012: 302-354. Available from: http://www.stata-press.
com/data/r12/. Last accessed June 17, 2017.
 
C
lin
ic
oE
co
no
m
ic
s 
an
d 
O
ut
co
m
es
 R
es
ea
rc
h 
do
w
nl
oa
de
d 
fr
om
 h
ttp
s:
//w
w
w
.d
ov
ep
re
ss
.c
om
/ b
y 
13
0.
22
5.
19
8.
22
4 
on
 1
2-
O
ct
-2
01
7
F
or
 p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
